Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.73 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799475 | 0.92 | VDR (0.78) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL10820222 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9009928 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9009884 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL23752369 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL23752370 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL13666147 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9010345 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL859793 | 0.92 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL798548 | 0.92 | VDR (0.76) | VDRCYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | claimed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2009067578-A2 | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131379-A1 | VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | VDR, CYP2R1, CYP24A1 | VDR 1/4885CYP24A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.